Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Edwards Lifesciences Corporation
EW
NYSE·Healthcare·Medical - Devices·Mkt cap $53.0B
$94.10
▲ +2.29%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$72.30 - $94.47
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 19.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary medical technologies
- Strong research and development pipeline
- Global distribution network
- First-mover advantage in minimally invasive cardiac solutions
Bear Case
2 risks
- Average volatility.
- Significant premium - growth priced in
Growth
Stable outlook
Aging global population
Value
Significant premium - growth priced in
Momentum
Strong
+13.5% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying EW right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 21, 2026
APR 23, 2026
Reported EPS of $0.78 vs $0.73 consensus (+7.0% surprise). Revenue of $1.6B vs $1.6B expected (+3.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+7.0%
Next: Apr 21, 2026
Revenue trend · last 8Q
—
—
+9%
+6%
+11%
+15%
+13%
+17%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$1.4B
$1.4B
$1.4B
$1.4B
$1.5B
$1.6B
$1.6B
$1.6B
Margins · last 8Q
Gross
78.2%
Operating
31.2%
Profit
23.1%
Wall Street consensus
13 analysts · 69% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
69%
Hold
31%
Sell
0%
Median Price Target
$94.00
▼ -0.1% vs $94.10
Latest: BTIG · Jun 30, 2026
6 analysts covering